Applied regulatory science research to evaluate and treat cardiotoxicity of oncology therapeutics
Food and Drug Administration
The goal of this funding opportunity announcement is to support applied regulatory science research to evaluate and treat cardiotoxicity of oncology therapeutics. The main outcomes of this work will be publications and presentations; however, FDA staff anticipate substantial involvement in study design and reviewing interim deliverables to ensure that the studies develop practical approaches and solutions that have the potential to inform regulatory decision making in the future. We anticipate organizing regular calls with funded investigators to support the collaboration with FDA - reviewing annual reports would be insufficient to ensure that direction of the research addresses FDA's needs. OCE is interested in supporting research that improve the detection, monitoring and treatment of cardiotoxicity of oncology therapeutics. Specific areas of interest include: -Standardize Definitions: Develop clear definitions for different types and grades of cardiotoxicity -Biomarkers and Imaging: Standardize the use of biomarkers and imaging techniques for assessing cardiotoxicity in oncology trials -Functional Measures: Define consistent criteria for evaluating cardiac function -Monitoring P
Deadline
Not published. Check the funder's page.
Who can apply
Open to: City or township governments; Native American tribal organizations (other than Federally recognized tribal governments); Special district governments; Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"; Small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; State governments; Native American tribal governments (Federally recognized).
Sources
Grants.gov. Last updated 2026-10-26.
Always confirm eligibility and deadlines on the funder's own page before applying.